For reprint rights or to purchase a copy of your Daily Journal photo, email Jeremy_Ellis@dailyjournal.com for prices or call 213-229-5424.

To buy more copies, call 866-531-1492 or email subscribe@dailyjournal.com
This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...

Mergers & Acquisitions

Jan. 25, 2013

Gibson, Latham advise on latest Allergan purchase

Gibson, Dunn & Crutcher LLP represented Irvine-based Allergan Inc. in its purchase of MAP Pharmaceuticals Inc. for $958 million. Allergan will pay $25 a share, according to the agreement announced late Tuesday.


By David Ruiz


Daily Journal Staff Writer


Gibson, Dunn & Crutcher LLP represented Irvine-based Allergan Inc. in its agreement to purchase Map Pharmaceuticals Inc. for $958 million, or $25 a share. The companies announced the deal late Tuesday.


Map Pharmaceuticals develops neurological drugs, such as its migraine treatment for adults, Levadex.


Irvine-based partner Terrence R. Allen and Palo Alto-based partner Gregory T. Davidson c...

To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!

Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)

Already a subscriber?

Enewsletter Sign-up



By using our website, you agree to our use of cookies in accordance with our cookie policy. You can learn more about how we use cookies by reviewing our Privacy Policy here.